Syndax Pharmaceuticals (SNDX) Trading Down 0%

Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s share price dropped 0% on Friday . The company traded as low as $10.67 and last traded at $10.84. Approximately 999,930 shares were traded during mid-day trading, an increase of 138% from the average daily volume of 419,694 shares. The stock had previously closed at $10.84.

SNDX has been the topic of a number of research analyst reports. ValuEngine raised shares of Syndax Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, March 20th. Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, January 5th. Morgan Stanley cut their price target on shares of Syndax Pharmaceuticals from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Wednesday, March 14th. B. Riley initiated coverage on shares of Syndax Pharmaceuticals in a report on Friday, January 5th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, BidaskClub raised shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $23.86.

How to Become a New Pot Stock Millionaire

The firm has a market capitalization of $361.33, a price-to-earnings ratio of -3.74 and a beta of 1.13.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Monday, March 5th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.04). The business had revenue of $1.19 million for the quarter, compared to analysts’ expectations of $0.75 million. Syndax Pharmaceuticals had a negative net margin of 2,884.34% and a negative return on equity of 63.51%. The firm’s revenue was up 290.2% compared to the same quarter last year. research analysts expect that Syndax Pharmaceuticals Inc will post -3.52 EPS for the current fiscal year.

In other Syndax Pharmaceuticals news, insider Peter Ordentlich sold 7,500 shares of the company’s stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $15.00, for a total transaction of $112,500.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 24.10% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. HighPoint Advisor Group LLC purchased a new stake in Syndax Pharmaceuticals during the fourth quarter valued at about $102,000. Trexquant Investment LP bought a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at about $133,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at about $154,000. Dimensional Fund Advisors LP bought a new stake in shares of Syndax Pharmaceuticals during the second quarter valued at about $192,000. Finally, California State Teachers Retirement System increased its position in shares of Syndax Pharmaceuticals by 60.9% during the second quarter. California State Teachers Retirement System now owns 15,587 shares of the company’s stock valued at $218,000 after buying an additional 5,900 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Syndax Pharmaceuticals (SNDX) Trading Down 0%” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3336354/syndax-pharmaceuticals-sndx-trading-down-0.html.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

AK Steel  versus Its Peers Head-To-Head Contrast
AK Steel versus Its Peers Head-To-Head Contrast
Analysts Anticipate First Industrial Realty Trust, Inc.  Will Announce Earnings of $0.38 Per Share
Analysts Anticipate First Industrial Realty Trust, Inc. Will Announce Earnings of $0.38 Per Share
TPI Composites  Expected to Announce Earnings of $0.03 Per Share
TPI Composites Expected to Announce Earnings of $0.03 Per Share
Brokerages Expect Kinsale Capital Group  to Announce $0.36 Earnings Per Share
Brokerages Expect Kinsale Capital Group to Announce $0.36 Earnings Per Share
President Trump  Market Capitalization Reaches $0.00
President Trump Market Capitalization Reaches $0.00
EDRCoin  Tops 24 Hour Volume of $2,782.00
EDRCoin Tops 24 Hour Volume of $2,782.00


© 2006-2018 Ticker Report. Google+.